SITC's Guide to Managing Immunotherapy Toxicity
Ernstoff, Marc (ed)
SITC's Guide to Managing Immunotherapy Toxicity - United States : Springer, 2019
Overview of Anti-CLA-4 agents - ipilimunab and tremelimumab; Overview of PD-1 and PD-L1 inhibitors; Indication and toxicities of immune checkpoint inhibitor combinations; General principles of immune-related toxicities; Dermatologic toxicities - rash, mucosal irritation, and pruritus; Muskuloskeletal and rheumatologic toxicities; Immune-related gastrointestinal toxicities; Pneumotoxicity associated with immune checkpoint blockades; Immune-related endocrinopathies associated with immune checkpoint inhibitors; Neurologic adverse events and neurologic complications; Cardiovascular toxicities related to immune checkpoint inhibitors; Renal toxicities associated with immune checkpoint inhibitors; Haematologic toxicities of apparent immune-related origins; Ocular toxicities caused by immune dysregulation; Safety and regulation of immune checkpoint inhibitors in special patient populations; Cancer-related fatigue in patients of immune checkpoint inhibitor therapy; Cost-effectiveness and financial toxicity of new cancer therapies
SITC's Guide to Managing Immunotherapy Toxicity is a practical reference to managing side effects associated with FDA-approved cancer immunotherapy drugs
0826172148 9780826172143
Immunotherapy
Oncology
SITC's Guide to Managing Immunotherapy Toxicity - United States : Springer, 2019
Overview of Anti-CLA-4 agents - ipilimunab and tremelimumab; Overview of PD-1 and PD-L1 inhibitors; Indication and toxicities of immune checkpoint inhibitor combinations; General principles of immune-related toxicities; Dermatologic toxicities - rash, mucosal irritation, and pruritus; Muskuloskeletal and rheumatologic toxicities; Immune-related gastrointestinal toxicities; Pneumotoxicity associated with immune checkpoint blockades; Immune-related endocrinopathies associated with immune checkpoint inhibitors; Neurologic adverse events and neurologic complications; Cardiovascular toxicities related to immune checkpoint inhibitors; Renal toxicities associated with immune checkpoint inhibitors; Haematologic toxicities of apparent immune-related origins; Ocular toxicities caused by immune dysregulation; Safety and regulation of immune checkpoint inhibitors in special patient populations; Cancer-related fatigue in patients of immune checkpoint inhibitor therapy; Cost-effectiveness and financial toxicity of new cancer therapies
SITC's Guide to Managing Immunotherapy Toxicity is a practical reference to managing side effects associated with FDA-approved cancer immunotherapy drugs
0826172148 9780826172143
Immunotherapy
Oncology